A history of cancer treatment prior to percutaneous coronary intervention was not associated with worse 14-year cardiovascular mortality compared to controls (HR 0.95; 95% CI 0.76 to 1.20).
Cohort (n=15,008)
No
Stented PCI patients (n=15,008)
Cancer treatment pre-PCI vs No cancer treatment pre-PCI
Cardiovascular mortality — HR 0.95 (0.76 to 1.20), p=0.31
Estimación del efecto: HR 0.95 (95% CI 0.76 to 1.20)
Tasa de eventos absoluta: 31.4% vs 27.7%
valor p: p=0.31
BACKGROUND: Cardiovascular disease and cancer increasingly coexist, yet relationships between cancer and long-term cardiovascular outcomes post-percutaneous coronary intervention (PCI) are not well studied. METHODS AND RESULTS: We examined stented PCI patients at Duke (1996-2010) using linked data from the Duke Information Systems for Cardiovascular Care and the Duke Tumor Registry (a cancer treatment registry). Our primary outcome was cardiovascular mortality. Secondary outcomes included composite cardiovascular mortality, myocardial infarction, or repeat revascularization and all-cause mortality. We used adjusted cause-specific hazard models to examine outcomes among cancer patients (cancer treatment pre-PCI) versus controls (no cancer treatment pre-PCI). Cardiovascular mortality was explored in a cancer subgroup with recent (within 1 year pre-PCI) cancer and in post-PCI cancer patients using post-PCI cancer as a time-dependent variable. Among 15 008 patients, 3.3% (n=496) were cancer patients. Observed rates of 14-year cardiovascular mortality (31.4% versus 27.7%, P=0.31) and composite cardiovascular death, myocardial infarction, or revascularization (51.1% versus 55.8%, P=0.37) were similar for cancer versus control groups; all-cause mortality rates were higher (79.7% versus 49.3%, P<0.01). Adjusted risk of cardiovascular mortality was similar for cancer patients versus controls (hazard ratio 0.95; 95% CI 0.76 to 1.20) and for patients with versus without recent cancer (hazard ratio 1.46; 95% CI 0.92 to 2.33). Post-PCI cancer, present in 4.3% (n=647) of patients, was associated with cardiovascular mortality (adjusted hazard ratio 1.51; 95% CI 1.11 to 2.03). CONCLUSIONS: Cancer history was present in a minority of PCI patients but was not associated with worse long-term cardiovascular outcomes. Further investigation into PCI outcomes in this population is warranted.
Building similarity graph...
Analyzing shared references across papers
Loading...
Hess et al. (Tue,) conducted a cohort in Stented PCI patients (n=15,008). Cancer treatment pre-PCI vs. No cancer treatment pre-PCI was evaluated on Cardiovascular mortality (HR 0.95, 95% CI 0.76 to 1.20, p=0.31). A history of cancer treatment prior to percutaneous coronary intervention was not associated with worse 14-year cardiovascular mortality compared to controls (HR 0.95; 95% CI 0.76 to 1.20).
synapsesocial.com/papers/6a06c70b2edded7c7b84142f — DOI: https://doi.org/10.1161/jaha.115.001779
Connie N. Hess
University of Colorado Denver
Matthew T. Roe
American College of Cardiology
Robert M. Clare
Heart Failure & Transplant
Journal of the American Heart Association
Duke Medical Center
Uppsala University
Clinical Research Institute
Building similarity graph...
Analyzing shared references across papers
Loading...